Xcout Intel
Vico Therapeutics competitors & alternatives
The 12 closest competitors and alternatives to Vico Therapeutics among biotechnology companies — ranked by similarity to what Vico Therapeutics actually does, not by market-cap band.
Subscribe to see Vico Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Vico Therapeutics
Vico Therapeutics is a neurology genetic medicine and biotechnology company pioneering targeted treatments for devastating disorders from its location at the BioScience Park.
Vico Therapeutics at a glance
Vico Therapeutics is a biotechnology company headquartered in Netherlands. Its most recent funding round, Series B, raised $70.7M in June 2024. Xcout tracks 1 named person at Vico Therapeutics, including Micah Mackison (Chief Executive Officer).
Vico Therapeutics leadership
- Micah MackisonChief Executive Officer
Vico Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $70.7M | 3 named | |
| Series B | $60M | — | |
| — | $31M | 9 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Vico Therapeutics competitors
Ranked by semantic similarity — how close each company is to Vico Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Neuron23 is a biotechnology company founded in 2018 that focuses on developing precision therapeutics for genetic diseases. Headquartered in South San Francisco, California, the company relies on a team of scientific experts and entrepreneurs.
Similar biotechnology company
Actio Biosciences is a privately held biotechnology company utilizing genomic medicine to discover and develop treatments for rare diseases and epilepsy.
Biotech
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Life Science
ReCode Therapeutics is a clinical-stage genetic medicines company headquartered in Menlo Park, California, and Durham, North Carolina. The company leverages proprietary delivery systems to power a new class of disease-modifying genetic therapies.
Similar biotechnology company
Nido Biosciences, Inc. is a clinical-stage holding and biotechnology company headquartered in Watertown, Massachusetts. The company focuses on discovering and advancing treatments for debilitating neurological diseases, including the development of targeted drugs.
Biotech
Verge Genomics develops a proprietary AI and machine learning platform utilizing human brain data to transform neuroscience drug discovery and precision neurology. The company provides foundation models and analytical tools to pharmaceutical and biotechnology developers for target discovery, biomarker identification, and clinical trial patient stratification.
Biotech
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Healthcare & Life Sciences
ViaNautis Bio Ltd. is a groundbreaking nanomedicine company headquartered in Cambridge, UK, at the forefront of genetic therapies. The company leverages its proprietary polyNaut platform to develop novel products for delivering genetic medicines.
Similar biotechnology company
Scenic Biotech is a biotechnology company headquartered in Amsterdam, Netherlands, that advances modifier therapy as an approach to treating genetic disorders by uncovering novel genome pathways.
Similar biotechnology company
Aspen Neuroscience, Inc. is a clinical-stage private biotechnology company headquartered in San Diego, California. The company focuses on developing personalized autologous cell therapies for neurodegenerative diseases.
Similar biotechnology company
Coave Therapeutics is a clinical-stage biotechnology company headquartered in Paris, France. The company focuses on developing life-changing gene therapies targeting rare ocular and central nervous system diseases.
Similar biotechnology company
SparingVision is a genomic and gene therapy medicines company translating pioneering science into vision-saving treatments, with US headquarters located in Boston, Massachusetts.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Vico Therapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Vico Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →